Alcohol-Induced Portal Hypertension Presenting With Massive Ascites-A Case Report

Authors

  • Karunya shree .G.V
  • Aishwarya Balasubramaniam
  • M. Dheenadhayalan
  • K. Karthickeyan
  • P. Shanmugasundaram
  • M.K.Sundar Sri

Keywords:

Portal hypertension, Ascites, Chronic alcoholism, Decompensated liver disease, Cirrhosis, Case report

Abstract

Background: Portal hypertension and ascites are serious complications of chronic liver disease. In alcohol-related cirrhosis, recurrent ascites despite optimal therapy may suggest rare vascular entities such as porto-sinusoidal vascular disease (PSVD), which can mimic cirrhosis but follow a different clinical course.

Case Presentation: A 47-year-old male with a 30-year history of chronic alcohol use and comorbid diabetes and hypertension presented with abdominal distension, pedal oedema, dyspnoea, and oliguria. He had two prior admissions for similar complaints. Examination revealed icterus, ascites, anasarca, and mild splenomegaly. Laboratory tests showed anaemia, thrombocytopenia, and elevated transaminases. Ultrasound suggested chronic liver disease with ascites. The patient was treated with intravenous furosemide, oral spironolactone, propranolol, antibiotics, and underwent large-volume paracentesis. Supportive measures included a salt-restricted, high-protein diet. Clinical improvement was noted during hospitalization. He was diagnosed with decompensated liver disease with portal hypertension, most likely due to alcoholic cirrhosis. However, recurrent ascites despite therapy raised the possibility of an overlapping vascular liver disorder such as PSVD.

Conclusion: This case highlights the need to consider alternative diagnoses, such as PSVD, in patients with alcohol-induced liver disease who experience frequent decompensations. Multidisciplinary management, alcohol cessation counselling, and long-term monitoring are crucial. Advanced diagnostics like HVPG measurement or liver biopsy may help differentiate atypical presentations and guide therapy.

Downloads

Download data is not yet available.

References

AASLD Practice Guidance on risk stratification and management in portal hypertension. Hepatology. 2024.

Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol. 2019;13(4):293–305.

Ginès P, Cárdenas A, Arroyo V, Rodés J. Refractory ascites. Gastroenterol Hepatol. 2009;13:47–55.

Krag A, Borup T, Møller S, Henriksen JH, Bendtsen F. Management of refractory and recurrent ascites. J Hepatol. 2012;56(2):348–54.

Patel SS, et al. Management of ascites and volume overload in patients with cirrhosis. Curr Hepatol Rep. 2023;22:12–18. (PMCID: PMC10857675)

Kazankov K, et al. Evaluation and management of patients with refractory ascites. Clin Liver Dis. 2019;23(4):589–607. (PMCID: PMC6676543)

Appenrodt B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction: a randomized pilot study. Liver Int. 2008;28(7):1019–25.

Mahmood S, et al. Oral midodrine versus albumin in cirrhotics undergoing large-volume paracentesis: a pilot RCT. Eur J Gastroenterol Hepatol. 2018;30(12):1421–6. (PMID: 30312183)

Singh V, et al. Midodrine in patients with refractory or recurrent ascites: a randomized controlled trial. J Hepatol. 2012;56(2):348–54.

Caraceni P, Tufoni M, Zaccherini G, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomized controlled trial. Lancet. 2018;391(10138):2417–29. (PMCID: PMC11945444)

Chang PE, et al. Portal hypertension: pathogenesis and management of decompensated cirrhosis. Gastroenterol Hepatol. 2022;13(4):293–305.

AASLD Practice Guidance: risk stratification and portal hypertension. Hepatology. 2024.

Appenrodt B, et al. Diuretic therapy in ascites: role of spironolactone and furosemide. J Hepatol. 2020;73(4):891–902.

Schouten JN, et al. Idiopathic non-cirrhotic portal hypertension: five-year outcomes from a European cohort. Hepatol Int. 2023;17(1):50–58.

Nakanuma Y, et al. Idiopathic non-cirrhotic portal hypertension: a global review. J Clin Gastroenterol. 2022;56(6):501–10.

Chen Y, et al. Role of TIPS in recurrent ascites due to porto-sinusoidal vascular disease. World J Gastroenterol. 2021;27(22):3163–71.

Liu Y, et al. Epidemiology and outcomes of idiopathic non-cirrhotic portal hypertension in Asia: a cohort study. Hepatol Res. 2022;52(4):378–86.

Lipperheide A, et al. Outcomes of TIPS in non-cirrhotic portal hypertension: a prospective study. Radiology. 2024;310(1):145–52.

Blanco M, et al. Histological and hemodynamic features of porto-sinusoidal vascular disease: a multicenter study. Gut. 2023;72(5):897–905.

Olivera MJ, et al. Predictors of survival in idiopathic non-cirrhotic portal hypertension: ascites as a key marker. J Hepatol. 2022;77(2):330–7.

Downloads

Published

2025-07-08

How to Cite

1.
.G.V K shree, Balasubramaniam A, Dheenadhayalan M, Karthickeyan K, Shanmugasundaram P, Sri M. Alcohol-Induced Portal Hypertension Presenting With Massive Ascites-A Case Report. J Neonatal Surg [Internet]. 2025Jul.8 [cited 2025Sep.21];14(32S):4265-9. Available from: https://jneonatalsurg.com/index.php/jns/article/view/8108

Similar Articles

You may also start an advanced similarity search for this article.